Zensar’s business solutions are designed to deliver value across operations, employee productivity, management reporting and customer engagement initiatives.
It continuously enhances its digital offerings and developing them as a key differentiator. It recently enhanced its Return on Digital® offerings and introduced a new version called New and Exponential Technologies (or RoD NeXT), which leverages emerging technologies such as artificial intelligence and smart platforms to deliver value to clients.
Its proprietary autonomics-based smart platform Vinci™ uses AI and ML capabilities to deliver prescriptive analytics and real-time dashboarding capabilities. It aims to provide ubiquitous connectivity, omnichannel service interaction and security and compliance.
Investments and Innovation
Zensar drives its innovation agenda through its innovation lab, Zenlabs, which conducts research on technologies such as enterprise and conversational AI, blockchain and augmented reality.
Its innovation-led strategy has resulted in the filing of 55 patents to date. A case in point is Zeva, a voice assistant expected to have multiple applications across enterprise customers.
It has plans to set up 3 more research centers, including one in the US, to offer on-shore or near-shore support to its key customers.
Partnership and Ecosystem
Zensar has deep enterprise-wide partnerships with technology providers such as IBM, Oracle and Pega. It has a global Pega CoE focused on innovation-driven projects as well as building project-based accelerators.
Its partnership with Oracle has resulted in investment in 25+ cloud projects supported by a dedicated cloud lab.
DISCLAIMER: This graphic was published by Avasant LLC as part of a larger research document and should be evaluated in the context of the entire document. The document is available upon request from Avasant website. Avasant does not endorse any provider, product or service depicted in its research publications, including RadarViewTM, and does not advise users to select only those providers recognized in these publications. Avasant’s research publications are based on information from best available sources and Avasant’s opinion at the time of publication, and their contents should not be construed as statements of fact. Avasant disclaims all warranties, expressed or implied, with respect to this research, including and warranties of merchantability or fitness for a particular purpose.